Literature DB >> 16097063

HBeAg negative serological status and low viral replication levels characterize chronic hepatitis B virus-infected women at reproductive age in Greece: a one-year prospective single center study.

Ioannis S Elefsiniotis1, Irene Glynou, Ioanna Magaziotou, Konstantinos D Pantazis, Nikolaos V Fotos, Hero Brokalaki, Helen Kada, George Saroglou.   

Abstract

AIM: To evaluate the seroprevalence of hepatitis B surface antigen (HBsAg) in 13 581 women at reproductive age and the hepatitis B e antigen (HBeAg)/anti-HBe status as well as serum hepatitis B virus (HBV)-DNA levels in a subgroup of HBsAg(+) pregnant women at labor in Greece.
METHODS: Serological markers were detected using enzyme immunoassays. Serum HBV-DNA was determined by a sensitive quantitative PCR assay. Statistical analysis of data was based on parametric methodology.
RESULTS: Overall, 1.156% of women were HBsAg(+) and the majority of them (71.3%) were Albanian. The prevalence of HBsAg was 5.1% in Albanian women, 4.2% in Asian women and 1.14% in women from Eastern European countries. The prevalence of HBsAg in African (0.36%) and Greek women (0.29%) was very low. Only 4.45% of HBsAg(+) women were also HBeAg(+) whereas the vast majority of them were HBeAg(-)/anti-HBe(+). Undetectable levels of viremia (<200 copies/mL) were observed in 32.26% of pregnant women at labor and 29.03% exhibited extremely low levels of viral replication (<400 copies/mL). Only two pregnant women exhibited extremely high serum HBV-DNA levels (>10 000 000 copies/mL), whereas 32.26% exhibited HBV-DNA levels between 1 500 and 40 000 copies/mL.
CONCLUSION: The overall prevalence of HBsAg is relatively low among women at reproductive age in Greece but is higher enough among specific populations. The HBeAg(-)/anti-HBe(+) serological status and the extremely low or even undetectable viral replicative status in the majority of HBsAg(+) women of our study population, suggest that only a small proportion of HBsAg(+) women in Greece exhibit a high risk for vertical transmission of the infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097063      PMCID: PMC4398741          DOI: 10.3748/wjg.v11.i31.4879

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

Review 1.  Hepatitis B maternal-fetal transmission in Southern Europe.

Authors:  G Papaevangelou; G Farmaki; H Kada
Journal:  Intervirology       Date:  1998       Impact factor: 1.763

2.  Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece.

Authors:  A Malamitsi-Puchner; S Papacharitonos; D Sotos; L Tzala; M Psichogiou; A Hatzakis; A Evangelopoulou; S Michalas
Journal:  Eur J Epidemiol       Date:  1996-06       Impact factor: 8.082

3.  Decline of hepatitis B infection in Greece.

Authors:  M Stamouli; V Gizaris; G Totos; G Papaevangelou
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

4.  Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan.

Authors:  Yao-Jong Yang; Ching-Chuan Liu; Te-Jen Chen; Meng-Feng Lee; Sheng-Hsien Chen; Hsiang-Hung Shih; Mei-Hwei Chang
Journal:  Pediatr Infect Dis J       Date:  2003-07       Impact factor: 2.129

5.  Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission.

Authors:  Ann Söderström; Gunnar Norkrans; Magnus Lindh
Journal:  Scand J Infect Dis       Date:  2003

6.  Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies.

Authors:  Zhanhui Wang; Jin Zhang; Hong Yang; Xiuhui Li; Shujuan Wen; Yabing Guo; Jian Sun; Jinlin Hou
Journal:  J Med Virol       Date:  2003-11       Impact factor: 2.327

7.  Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants.

Authors:  Alexander Milne; David J West; Dang Van Chinh; Chris D Moyes; Gabriele Poerschke
Journal:  J Med Virol       Date:  2002-07       Impact factor: 2.327

8.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.

Authors:  M van Zonneveld; A B van Nunen; H G M Niesters; R A de Man; S W Schalm; H L A Janssen
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

9.  HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan.

Authors:  C E Stevens; R A Neurath; R P Beasley; W Szmuness
Journal:  J Med Virol       Date:  1979       Impact factor: 2.327

10.  Hepatitis B immunization programme: lessons learnt in Greece.

Authors:  G Papaevangelou
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.